最新ニュース Genius Sports (NYSE:GENI) 株価情報

Genius Sports

Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.

Genius Sports Ltd

GENIUS PRODS INC by Genius Products, Inc.

Genie Energy Ltd. Class B Common Stock Stock

Genie Energy Ltd

Genius Group Ltd

GENIX PHARMACEUTICALS CP by GENIX PHARMACEUTICALS CORP.

Genix Pharmaceuticals Corp

WIIM

BLUE

Bluebird Bio shares are trading higher after the company confirmed it received an unsolicited non-binding proposal from Ayrmid.

FutureFuel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FF#NYSE">FF</a>) reported quarterly earnings of $0.06 per share. This is a 88.68 percent decrease over earnings of $0.53 per share from the same period last year. The company reported $61.51 million in sales this quarter. This is a 33.15 percent decrease over sales of $92.01 million the same period last year.

Earnings

News

FutureFuel Q4 EPS $0.06 Down From $0.53 YoY, Sales $61.51M Down From $92.01M YoY

VGAS

Verde Clean Fuels Q4 EPS $(0.14) Down From $(0.11) YoY

General

Enzo Biochem To Voluntarily Delist Its Common Stock From The New York Stock Exchange ; Effective On Or About April 17, 2025

In a key leadership development, Ron Pitters, a Director of the Company, has been appointed as Chief Operating Officer. Ron brings a wealth of experience in technology, fintech, and global business leadership, having held senior roles at Axos Financial, Inc. His extensive expertise spans technology, capital markets, product development, and business innovation, making him the ideal fit to help drive ALT5's global growth.

Management

ALTS

ALT5 Sigma Announces Ron Pitters Appointed As New Chief Operating Officer

KPLT

Katapult Holdings shares are trading lower after the company reported Q4 financial results and missed its revenue estimate.

Nippon Steel and United States Steel Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) are reportedly negotiating with the Trump administration to revive their $14 billion merger by significantly boosting investments in U.S. Steel's<a href="https://www.benzinga.com/news/guidance/25/03/44432858/us-steel-faces-q1-pressures-but-eyes-long-term-gains-from-br2-nippon-partnership"> Rust Belt facilities.&nbsp;</a>
The Details: According to <a href="https://www.semafor.com/article/03/27/2025/us-steel-and-nippon-are-in-talks-to-revive-merger-that-trump-had-threaten-to-block">a report</a> from Semafor, sources familiar with the discussions said the Japanese steelmaker has proposed raising its initial $2.7 billion commitment to upgrade U.S. Steel plants to as much as $7 billion.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/03/44537429/cathie-wood-doubles-down-on-2600-tesla-stock-price-prediction">Cathie Wood Doubles Down On $2,600 Tesla Stock Price Prediction</a>
The deal was initially blocked by the Biden administration over national security concerns, and now hinges on strategic concessions. While President Donald Trump <a href="https://www.benzinga.com/25/02/43576917/trump-says-reconsiders-nippon-steels-149-billion-us-steel-deal-theyve-agreed-to-invest-heavilyas-opposed-to-own-it">previously opposed</a> the acquisition, he signaled openness in February to Nippon taking a<a href="https://www.benzinga.com/markets/commodities/25/03/44423382/billionaire-stanley-druckenmiller-boosts-us-steel-stake-by-143-is-he-betting-on-merger"> minority stake</a> or structuring the deal as an investment rather than a full buyout.&nbsp;
The revised terms would preserve the $55-per-share acquisition price and Nippon would begin making sizable capital investments into U.S. Steel as soon as possible, the sources said.&nbsp;
Legal and political hurdles remain. Both companies are involved in a lawsuit against the U.S. government, which recently sought deadline extensions to continue merger talks. The United Steelworkers union and <a href="https://www.benzinga.com/news/mid-cap/25/01/43275376/who-is-alan-kestenbaum-activist-investor-ancoras-pick-to-lead-us-steel">activist investors </a>like Ancora have also voiced opposition and are lobbying the Trump administration for alternative plans.&nbsp;
X Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, shares of U.S. Steel climbed in early trading, but ended Friday's session 0.02% lower at $43.00 amid a broad market sell-off. 
Read Next:<a href="https://www.benzinga.com/government/regulations/25/03/44517885/trump-slaps-25-tariffs-on-autos-what-it-means-for-your-next-car-purchase">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44517885/trump-slaps-25-tariffs-on-autos-what-it-means-for-your-next-car-purchase">Trump Slaps 25% Tariffs On Autos: What It Means For Your Next Car Purchase</a>&nbsp;</li>
</ul>
Image: Shutterstock

Global

Movers

Nippon Attempts To Revive US Steel Deal With Larger Capital Investments

ALT5 Sigma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTS#NASDAQ">ALTS</a>) reported $5.42 million in sales this quarter.

ALT5 Sigma Q4 Revenue Of $5.42M

XoS shares are trading higher. The company reported Q4 financial results.

bluebird bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) ("bluebird") today confirmed it has received an unsolicited non-binding written proposal (the "Ayrmid Proposal") from Ayrmid Ltd ("Ayrmid") to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone.
As previously announced on February 21, 2025, bluebird entered into a definitive agreement (the "Merger Agreement") with funds managed by global investment firms Carlyle and SK Capital Partners, LP to be acquired and taken private for $3.00 per share in cash and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone, contingent upon certain offer conditions (the "Merger"). bluebird previously engaged in discussions with Ayrmid as part of its comprehensive review of strategic alternatives. Ayrmid did not submit any proposal to bluebird as part of that process. The Ayrmid Proposal is subject to certain conditions and further negotiations between the parties, including confirmatory diligence.

bluebird bio Confirms Receipt Of An Unsolicited Non-Binding Proposal From Ayrmid To Acquire Bluebird For An Upfront Cash Payment Of $4.50 Per Share And A One-Time Contingent Value Right Of $6.84 Per Share Payable Upon Achievement Of A Net Sales Milestone

Benjamin Cowen, founder of IntoTheCryptoverse, warns that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is approaching another &#8220;death cross.&#8221;
What Happened: In a <a href="https://www.youtube.com/watch?v=e211pOyTVyI">podcast</a> published on Friday, Cowen said that Bitcoin will &#8220;likely have another death cross," meaning the 50-day simple moving average crossing below the 200-day simple moving average, if nothing changes in the next one to two weeks.
This would mark Bitcoin's third death cross in the current cycle, following September 2023 and August 2024. 
Historically, death crosses trigger short-term sell-offs but often lead to strong rallies afterward.
"What normally happens is Bitcoin goes into some longer drawn-out period where the price trends down&#8230; and then it leads to these moving averages converging back together," Cowen stated, adding that &#8220;just before it and then when it happens everyone starts screaming the death cross is here and then what normally happens after the death cross is the market then gets a rally.&#8221;
&nbsp;Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44537514/bitcoin-tumbles-below-85000-is-the-bull-run-over">Bitcoin Tumbles Below $85,000: Is The Bull Run Over?</a>
What's Next: Looking ahead, Cowen believes the critical support level to watch is $73,000. 
&#8220;If in the next pullback&#8230; it holds above $73,000, then there&#8217;s no guarantee with the market but it would suggest that the structure of the market remains intact,&#8221; he explained, comparing this to 2017&#8217;s pattern where Bitcoin tested its previous yearly high before continuing upward.
Price Action: In the past 24 hours, Bitcoin is down 4% to $83,700.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44506865/michael-saylors-unusual-bitcoin-plan-for-the-afterlife-making-everyone-richer-and-more-pow">Michael Saylor&#8217;s Unusual Bitcoin Plan For The Afterlife: &#8216;Making Everyone Richer And More Powerful&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Eyes $83,000 Breakdown: Is A Death Cross Coming?

Macro Economic Events

Politics

Economics

Canada PM Carney Says Trump Offered No Indication Of Pulling Back Tariffs On Canadian Autos, Steel, Aluminum

Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) has outperformed the market over the past 5 years by 29.53% on an annualized basis producing an average annual return of 46.14%. Currently, Viper Energy has a market capitalization of $5.80 billion. 
Buying $100 In VNOM: If an investor had bought $100 of VNOM stock 5 years ago, it would be worth $730.41 today based on a price of $44.19 for VNOM at the time of writing.
<h3>Viper Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743192909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

VNOM

Here's How Much $100 Invested In Viper Energy 5 Years Ago Would Be Worth Today

Guidance

GNLX

Genelux Q4 EPS ($0.95) Up From ($1.16) YoY

Canada's PM Carney Says President Trump Respected Canada's Sovereignty Today, Both In His Private And Public Comments

- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement -
- Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 -
- Continue to progress multiple novel, research-stage immunoprotective approaches -
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vrtx.com%2F&amp;esheet=54230222&amp;newsitemid=20250328622122&amp;lan=en-US&amp;anchor=Vertex+Pharmaceuticals+Incorporated&amp;index=1&amp;md5=8b0996d221294fdf9df4f4bb3c2785ac">Vertex Pharmaceuticals Incorporated</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) today announced several updates on the Company's type 1 diabetes (T1D) portfolio.

Biotech

VRTX

Vertex Announces Program Updates For Type 1 Diabetes Portfolio; VX-264 Phase 1/2 Enrollment And Dosing Complete In Parts A And B: VX-264 Was Generally Safe And Well Tolerated; Efficacy Data Are Not Supportive Of Further Clinical Advancement

BOXL

Boxlight Q4 EPS ($8.65) Up From ($9.35) YoY; Revenue $24.0M Down From $38.8M YoY

PTVE

Pactiv Evergreen Receives All Required Regulatory Approvals For Planned Acquisition By Novolex; Expected To Close On April 1, 2025

Aureus Greenway FY24 EPS $(0.02) Down From $0.04 YoY; Revenue $3.3M Down From $3.55M YoY

Entera Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTX#NASDAQ">ENTX</a>) reported quarterly losses of $(0.25) per share. The company reported quarterly sales of $181.000 thousand which beat the analyst consensus estimate of $139.000 thousand by 30.22 percent.

Earnings Beats

ENTX

Entera Bio FY 2024 GAAP EPS $(0.25), Sales $181.000K Beat $139.000K Estimate

Press Releases

Los Angeles Rams launch Next Gen Stats-powered, in-stadium highlights through new collaboration with Genius Sports

First-Of-Its-Kind "EA Sports Madden NFL Cast" to Stream Live Exclusively on Peacock for Texans-Chiefs Matchup on Saturday Dec. 21 at 1 P.M. ET

TNT Sports, in Collaboration with NBA 2K and Genius Sports, to Present NBA 2K25 DataCast Alternative Telecast on truTV & Max for 2024 Emirates NBA Cup Knockout Round Coverage

Genius Sports to Participate in the Annual Needham Growth Conference

Genius Sports Announces Pricing of Public Offering

Genius Sports Reaffirms 2024 Guidance and Announces Preliminary Unaudited Estimate of Fourth Quarter Cash, a Positive Net Cash Position in the Full-Year 2024

Genius Sports to Announce Fourth Quarter and Full Year 2024 Results on March 4

PANDA Interactive Sues Genius Sports & Sportradar for Anti-Competitive Conduct in Sports Betting Market

Genius Sports Reports Fourth Quarter and Full-Year 2024 Results and Announces 2025 Outlook for 21% Group Revenue Growth and 20% Group Adj. EBITDA Margin

New Deep Blue Audience Intelligence and Monetization Service to be Offered on Genius Sports' FANHub Platform

Comments

Genius Sports

ニュース

最新ニュース Genius Sports (NYSE:GENI) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル